香甲丸治疗晚期胃癌的效果及安全性分析

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (539 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the clinical efficacy and safety of Xiangjia Pills in the treatment of advanced gastric cancer. Methods Seventy-two patients with advanced gastric cancer who had failed second-line treatment in the Department of Oncology, Danyang Hospital of Traditional Chinese Medicine from June 2014 to May 2018 were included, and they were divided into the experimental group and the control group by random number table. There were 51 cases in the experimental group and 21 cases in the control group. The experimental group was treated with Xiangjia Pills combined with the best supportive treatment, which lasted for 15 consecutive days for one course of treatment, and at least two courses of treatment, until the disease progressed significantly or the drug could not be tolerated. The control group was treated with the best supportive treatment. The fatigue, poor appetite, Numerical rating scale (NRS) score, Karnofsky functional status (KPS) score, tumor markers, toxicity and side effects, and overall survival (OS) of patients in both groups were observed. Results In the experimental group, 51 patients entered the study, of which 2 cases fell out and 49 cases completed the study. All 21 patients in the control group completed the study. The effective rates of fatigue and poor appetite after treatment in the experimental group were significantly higher than those in the control group, with highly statistically significant differences (P < 0.01). There was no significant difference in NRS score between the experiment group and the control group after treatment (P ＞ 0.05). After treatment, the KPS score of the experimental group was higher than that of the control group, with statistically significant difference (P < 0.05). No significant blood and liver and kidney toxicity were observed in the experimental group, and 42.86% of the patients had decreased tumor markers. The average OS in the experimental group was longer than that in the control group, with statistically significant difference (P ＜ 0.05). Conclusion Xiangjia Pills can effectively treat advanced gastric cancer, increase the quality of life of patients, improve the symptoms of fatigue and poor appetite for gastric cancer. To some extent, the survival period is prolonged, and there is no obvious toxic side effect. It is worthy to promotion.

Key words： Xiangjia Pill Advanced gastric cancer Traditional Chinese medicine

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MA Jiheng WANG Guofang

Cite this article:

MA Jiheng WANG Guofang. Effect and safety analysis of Xiangjia Pills in the treatment of advanced gastric cancer[J]. 中国医药导报, 2020, 17(3): 115-119.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I3/115

[1] Ferlay J，Soerjomataram I，Dikshit R，et al. Cancer incidence and mortality worldwide： sources， methods and major patterns in GLOBOCAN 2012 [J]. Int J Cancer，2015，136（5）：E359-E386.
[2] 左婷婷，郑荣寿，曾红梅，等.中国胃癌流行病学现状[J].中国肿瘤临床，2017，44（1）：52-58.
[3] 汪荃，韩仁强，李莹，等.2015年江苏省胃癌流行现状及趋势分析[J]中国肿瘤，2019，28（11）：838-844.
[4] 张琪，刘产明，朱月琴.江苏省中医药传统知识保护名录汇编[M].南京，江苏凤凰科学技术出版社，2017：204.
[5] 中华人民共和国卫生部医政司.胃癌诊疗规范（2011年版）[J].中国医学前沿杂志：电子版，2012，4（5）：62-71.
[6] 郑筱萸.中药新药临床研究指导原则（试行）[M].北京，中国医药科技出版社，2002：135.
[7] 张松松，赵云娇，牛玉莹，等.晚期癌症患者癌痛的规范化治疗疗效评估（附115例）[J].现代肿瘤学杂志，2019， 27（17）：3114-3131.
[8] 李云，徐力.中重度肺癌疼痛患者中西医结合治疗对疼痛情况、生活质量评分、生存情况及安全性的影响[J].中国老年学杂志，2018，12（38）：5933-5935.
[9] 董智平，张静喆.中医治疗胃癌研究进展[J].中国中西医结合外科杂志，2019，25（2）：206-209.
[10] 国家技术监督局.中华人民共和国国家标准·中医临床诊疗术语疾病部分[M].北京：中国标准出版社，1997：11.
[11] 蒋树龙，花宝金.肿瘤发生发展痰瘀本质及其与肿瘤微环境关系探析[J].中国中医基础医学杂志，2015，21（11）：1417-1419.
[12] 卢冬雪，祁明浩，薛恬，等.刘沈林治疗晚期消化道肿瘤用药经验[J].世界中西医结合杂志，2017，12（8）：1064-1068.
[13] 程海波，吴勉华.周仲瑛教授“癌毒”学术思想探析[J].中华中医药杂志，2010，25（6）：866-869.
[14] 周骏，赵智强，刘晓芬.周仲瑛教授论治胃癌术后的经验[J].中医临床研究，2018，10（36）：1-3.
[15] 张琪，刘产明，朱月琴.江苏省中医药传统知识保护名录汇编[M].南京：江苏凤凰科学技术出版社，2017：2，204.
[16] 曹昌霞，王宏斌，杨如意，等.麝香对人胃癌细胞株移植瘤HER2，VEGF和肿瘤标志物的影响[J].河南医学研究，2018，27（23）：4225-4228.
[17] 董建.麝香保心丸与单硝酸异山梨酯缓释片联合治疗冠心病心绞痛的临床研究[J].中国现代医生，2019，57（30）：46-48，52.
[18] 王晓兰，宋佳玉，王建刚.壁虎抗肿瘤作用研究现状[J].中国实验方剂学杂志，2011，17（4）：218-220.
[19] 孙满强，胡凯文，杨新阶，等.胡凯文运用壁虎、蜈蚣药对治疗恶性肿瘤的临床经验[J]，中华中医药杂志，2019， 33（9）：3929-3931.
[20] 吴福林，董庆海，王涵，等.中药全蝎的研究进展[J]，辽宁中医药大学学报，2018，12（12）：108-111.
[21] 王春燕，彭康.彭康教授巧用全蝎免煎剂治疗头痛验案举隅[J].中国医药导报，2019，16（4）：141-144.
[22] 杨晓慧，李雁.中药蜈蚣抗肿瘤作用的研究进展[J].中成药，2017，39（2）：373-377.